Identification of Ovarian Cancer Metastatic miRNAs

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Vang, Souriya ^a   Wu, Hsin Ta ^a,b,c   Fischer, Andrew ^a   Miller, Daniel H ^a   MacLaughlan, Shannon ^d   Douglass, Elijah ^a   Steinhoff, Margaret ^d   Collins, Colin ^e   Smith, Peter J S ^f   Brard, Laurent ^g   Brodsky, Alexander S ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c Brown Univerity   (United States)

^d BROWN UNIVERSITY   (United States)

^e VANCOUVER PROSTATE CENTRE   (Canada)

^f UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^g SOUTHERN ILLINOIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; MICRORNA; MICRORNA 124; MICRORNA 146A; MICRORNA 150; MICRORNA 152; MICRORNA 185; MICRORNA 193A 5P; MICRORNA 21; MICRORNA 214; MICRORNA 29A; MICRORNA 31; MICRORNA 370; MICRORNA 431; MICRORNA 508 3P; MICRORNA 508 5P; MICRORNA 509 3 5P; MICRORNA 708; MICRORNA LET 7D; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CELL SURVIVAL; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; DRUG RESISTANCE; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; METASTASIS; NUCLEOTIDE SEQUENCE; OMENTAL METASTASIS; OVARY CARCINOMA; POLYMERASE CHAIN REACTION; PRIMARY TUMOR; QUANTITATIVE POLYMERASE CHAIN REACTION; RNA ANALYSIS; TUMOR SPHEROID; TUMOR VOLUME; UPREGULATION;

AGED; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; MIDDLE AGED; NEOPLASM METASTASIS; OVARIAN NEOPLASMS; RNA, NEOPLASM; SPHEROIDS, CELLULAR;

EID: 84874823707     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0058226     Document Type: Article

References (53)

1. Lengyel E, (2010) Ovarian cancer development and metastasis. Am J Pathol 177: 1053-1064.
2. Paris PL, Hofer MD, Albo G, Kuefer R, Gschwend JE, et al. (2006) Genomic profiling of hormone-naive lymph node metastases in patients with prostate cancer. Neoplasia 8: 1083-1089.
3. Shah SP, Morin RD, Khattra J, Prentice L, Pugh T, et al. (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461: 809-813.
4. Yachida S, Jones S, Bozic I, Antal T, Leary R, et al. (2010) Distant metastasis occurs late during the genetic evolution of pancreatic cancer. Nature 467: 1114-1117.
5. Bos PD, Zhang XH, Nadal C, Shu W, Gomis RR, et al. (2009) Genes that mediate breast cancer metastasis to the brain. Nature 459: 1005-1009.
6. Ramaswamy S, Ross KN, Lander ES, Golub TR, (2003) A molecular signature of metastasis in primary solid tumors. Nat Genet 33: 49-54.
7. Hynes RO, (2003) Metastatic potential: generic predisposition of the primary tumor or rare, metastatic variants-or both? Cell 113: 821-823.
8. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, et al. (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17: 1498-1503.
9. Tredan O, Galmarini CM, Patel K, Tannock IF, (2007) Drug resistance and the solid tumor microenvironment. J Natl Cancer Inst 99: 1441-1454.
10. Colella S, Richards KL, Bachinski LL, Baggerly KA, Tsavachidis S, et al. (2008) Molecular signatures of metastasis in head and neck cancer. Head Neck 30: 1273-1283.
11. Liu CJ, Liu TY, Kuo LT, Cheng HW, Chu TH, et al. (2008) Differential gene expression signature between primary and metastatic head and neck squamous cell carcinoma. J Pathol 214: 489-497.
12. Paris PL, Andaya A, Fridlyand J, Jain AN, Weinberg V, et al. (2004) Whole genome scanning identifies genotypes associated with recurrence and metastasis in prostate tumors. Hum Mol Genet 13: 1303-1313.
13. Adib TR, Henderson S, Perrett C, Hewitt D, Bourmpoulia D, et al. (2004) Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br J Cancer 90: 686-692.
14. Hibbs K, Skubitz KM, Pambuccian SE, Casey RC, Burleson KM, et al. (2004) Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am J Pathol 165: 397-414.
15. Lancaster JM, Dressman HK, Clarke JP, Sayer RA, Martino MA, et al. (2006) Identification of genes associated with ovarian cancer metastasis using microarray expression analysis. Int J Gynecol Cancer 16: 1733-1745.
16. Hudson LG, Zeineldin R, Stack MS, (2008) Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 25: 643-655.
17. Cowden Dahl KD, Symowicz J, Ning Y, Gutierrez E, Fishman DA, et al. (2008) Matrix metalloproteinase 9 is a mediator of epidermal growth factor-dependent e-cadherin loss in ovarian carcinoma cells. Cancer Res 68: 4606-4613.
18. Moss NM, Barbolina MV, Liu Y, Sun L, Munshi HG, et al. (2009) Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res 69: 7121-7129.
19. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, et al. (2008) Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68: 2329-2339.
20. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, et al. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33: e179.
21. Creighton CJ, Hernandez-Herrera A, Jacobsen A, Levine DA, Mankoo P, et al. (2012) Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma. PLoS One 7: e34546.
22. Grun B, Benjamin E, Sinclair J, Timms JF, Jacobs IJ, et al. (2009) Three-dimensional in vitro cell biology models of ovarian and endometrial cancer. Cell Prolif 42: 219-228.
23. Weigelt B, Lo AT, Park CC, Gray JW, Bissell MJ, (2010) HER2 signaling pathway activation and response of breast cancer cells to HER2-targeting agents is dependent strongly on the 3D microenvironment. Breast Cancer Res Treat 122: 35-43.
24. Rizvi I, Celli JP, Evans CL, Abu-Yousif AO, Muzikansky A, et al. (2010) Synergistic enhancement of carboplatin efficacy with photodynamic therapy in a three-dimensional model for micrometastatic ovarian cancer. Cancer Res 70: 9319-9328.
25. Rahmanzadeh R, Rai P, Celli JP, Rizvi I, Baron-Luhr B, et al. (2010) Ki-67 as a molecular target for therapy in an in vitro three-dimensional model for ovarian cancer. Cancer Res 70: 9234-9242.
26. Muranen T, Selfors LM, Worster DT, Iwanicki MP, Song L, et al. (2012) Inhibition of PI3K/mTOR Leads to Adaptive Resistance in Matrix-Attached Cancer Cells. Cancer Cell 21: 227-239.
27. Shield K, Ackland ML, Ahmed N, Rice GE, (2009) Multicellular spheroids in ovarian cancer metastases: Biology and pathology. Gynecol Oncol 113: 143-148.
28. Napolitano AP, Dean DM, Man AJ, Youssef J, Ho DN, et al. (2007) Scaffold-free three-dimensional cell culture utilizing micromolded nonadhesive hydrogels. Biotechniques 43: 494, 496-500.
29. Sharma SV, Lee DY, Li B, Quinlan MP, Takahashi F, et al. (2010) A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell 141: 69-80.
30. Krichevsky AM, Gabriely G, (2009) miR-21: a small multi-faceted RNA. J Cell Mol Med 13: 39-53.
31. Baek D, Villen J, Shin C, Camargo FD, Gygi SP, et al. (2008) The impact of microRNAs on protein output. Nature 455: 64-71.
32. Mukherji S, Ebert MS, Zheng GX, Tsang JS, Sharp PA, et al. (2011) MicroRNAs can generate thresholds in target gene expression. Nat Genet 43: 854-859.
33. Xiao C, Calado DP, Galler G, Thai TH, Patterson HC, et al. (2007) MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell 131: 146-159.
34. Zhou B, Wang S, Mayr C, Bartel DP, Lodish HF, (2007) miR-150, a microRNA expressed in mature B and T cells, blocks early B cell development when expressed prematurely. Proc Natl Acad Sci U S A 104: 7080-7085.
35. Wu Q, Jin H, Yang Z, Luo G, Lu Y, et al. (2010) MiR-150 promotes gastric cancer proliferation by negatively regulating the pro-apoptotic gene EGR2. Biochem Biophys Res Commun 392: 340-345.
36. Li YJ, Zhang YX, Wang PY, Chi YL, Zhang C, et al. (2011) Regression of A549 lung cancer tumors by anti-miR-150 vector. Oncol Rep.
37. Ma Y, Zhang P, Wang F, Zhang H, Yang J, et al. (2011) miR-150 as a potential biomarker associated with prognosis and therapeutic outcome in colorectal cancer. Gut.
38. Watanabe A, Tagawa H, Yamashita J, Teshima K, Nara M, et al. (2011) The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia 25: 1324-1334.
39. Lovat F, Valeri N, Croce CM, (2011) MicroRNAs in the pathogenesis of cancer. Semin Oncol 38: 724-733.
40. Garzon R, Marcucci G, Croce CM, (2010) Targeting microRNAs in cancer: rationale, strategies and challenges. Nat Rev Drug Discov 9: 775-789.
41. Zhou L, Qi X, Potashkin JA, Abdul-Karim FW, Gorodeski GI, (2008) MicroRNAs miR-186 and miR-150 down-regulate expression of the pro-apoptotic purinergic P2X7 receptor by activation of instability sites at the 3'-untranslated region of the gene that decrease steady-state levels of the transcript. J Biol Chem 283: 28274-28286.
42. Taganov KD, Boldin MP, Chang KJ, Baltimore D, (2006) NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A 103: 12481-12486.
43. Bhaumik D, Scott GK, Schokrpur S, Patil CK, Campisi J, et al. (2008) Expression of microRNA-146 suppresses NF-kappaB activity with reduction of metastatic potential in breast cancer cells. Oncogene 27: 5643-5647.
44. Garcia AI, Buisson M, Bertrand P, Rimokh R, Rouleau E, et al. (2011) Down-regulation of BRCA1 expression by miR-146a and miR-146b-5p in triple negative sporadic breast cancers. EMBO Mol Med 3: 279-290.
45. Suzuki Y, Kim HW, Ashraf M, Haider H, (2010) Diazoxide potentiates mesenchymal stem cell survival via NF-kappaB-dependent miR-146a expression by targeting Fas. Am J Physiol Heart Circ Physiol 299: H1077-1082.
46. Borst P, Rottenberg S, Jonkers J, (2008) How do real tumors become resistant to cisplatin? Cell Cycle 7: 1353-1359.
47. Casey RC, Burleson KM, Skubitz KM, Pambuccian SE, Oegema TR Jr, et al. (2001) Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids. Am J Pathol 159: 2071-2080.
48. Zietarska M, Maugard CM, Filali-Mouhim A, Alam-Fahmy M, Tonin PN, et al. (2007) Molecular description of a 3D in vitro model for the study of epithelial ovarian cancer (EOC). Mol Carcinog 46: 872-885.
49. Sodek KL, Ringuette MJ, Brown TJ, (2009) Compact spheroid formation by ovarian cancer cells is associated with contractile behavior and an invasive phenotype. Int J Cancer 124: 2060-2070.
50. Gene-E website. Available: http://www.broadinstitute.org/cancer/software/GENE-E/. Accessed 2013 Feb 18.
51. Lewis BP, Burge CB, Bartel DP, (2005) Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 120: 15-20.
52. Kertesz M, Ivino N, Unnerstall U, Gaul U, Segal E, (2007) The role of site accessibility in microRNA target recognition. Nat Genet 39: 1278-1284.
53. Nielsen BS, (2012) MicroRNA in situ hybridization. Methods Mol Biol 822: 67-84.